Vestmark Advisory Solutions Inc. Purchases New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vestmark Advisory Solutions Inc. acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 472,256 shares of the company’s stock, valued at approximately $4,656,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Recursion Pharmaceuticals by 116.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after purchasing an additional 2,817 shares in the last quarter. First Horizon Advisors Inc. bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $47,000. Allspring Global Investments Holdings LLC raised its stake in shares of Recursion Pharmaceuticals by 25.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock valued at $77,000 after acquiring an additional 2,050 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at approximately $79,000. Finally, Plancorp LLC bought a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at approximately $82,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total value of $106,457.10. Following the transaction, the director now owns 7,312,917 shares of the company’s stock, valued at $68,010,128.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10. Following the completion of the sale, the director now owns 7,312,917 shares in the company, valued at $68,010,128.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Tina Marriott sold 8,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $14.89, for a total value of $119,120.00. Following the sale, the chief operating officer now owns 639,982 shares of the company’s stock, valued at approximately $9,529,331.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 412,665 shares of company stock valued at $4,036,978. 19.96% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Trading Up 0.6 %

RXRX stock traded up $0.05 during trading on Friday, hitting $8.84. The company had a trading volume of 3,982,474 shares, compared to its average volume of 4,073,535. The company has a fifty day moving average price of $9.88 and a two-hundred day moving average price of $9.18. The company has a market cap of $2.07 billion, a P/E ratio of -5.70 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. The business had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Analyst Ratings Changes

RXRX has been the topic of several recent analyst reports. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. KeyCorp lifted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.